Исследование эффективности и безопасности элтромбопага у пациентов с МДС низкого риска и зависимостью от трансфузии тромбоцитов
Рандомизированное двойное слепое плацебо-контролируемое клиническое исследование II фазы в Японии, посвященное сравнению монотерапии элтромбопагом и плацебо у взрослых пациентов с миелодиспластическим синдромом (МДС) низкого риска и зависимостью от трансфузии тромбоцитов
This study is designed to evaluate the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk Myelodysplastic syndromes (LR-MDS).
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
This is a randomized, double-blind, placebo-controlled, Japanese local phase II study to evaluate the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk MDS (IPSS-R very low, low, intermediate risk with bone marrow blast count < 5% and cytogenetic very good, good or intermediate risk). Platelet transfusion dependence at baseline is defined as receiving platelet transfusion regularly with a frequency of 2 or more times within 4 weeks prior to randomization. Platelet transfusion should be performed for a patient with platelet counts < 20 X 10^9/L, or with hemorrhagic symptoms and platelet counts < 30 X 10^9/L.
The primary objective is to demonstrate superiority of eltrombopag versus placebo in terms of the proportion of participants who achieve platelet transfusion independence at Week 24.
Тип исследования
Тип исследования
Регистрация (Действительный)
Регистрация
Фаза
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
-
Aomori, Япония, 0308553
- Novartis Investigative Site
-
Chiba, Япония, 2600852
- Novartis Investigative Site
-
Fukushima, Япония, 9601295
- Novartis Investigative Site
-
Gifu, Япония, 5008513
- Novartis Investigative Site
-
Kumamoto, Япония, 8600008
- Novartis Investigative Site
-
Osaka, Япония, 5340021
- Novartis Investigative Site
-
Yamagata, Япония, 9909585
- Novartis Investigative Site
-
-
Chiba
-
Narita, Chiba, Япония, 2868523
- Novartis Investigative Site
-
-
Fukuoka
-
Kurume, Fukuoka, Япония, 8308543
- Novartis Investigative Site
-
-
Hiroshima
-
Ohtake, Hiroshima, Япония, 7390696
- Novartis Investigative Site
-
-
Hyōgo
-
Nishinomiya, Hyōgo, Япония, 6638501
- Novartis Investigative Site
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Япония, 9208530
- Novartis Investigative Site
-
-
Kanagawa
-
Isehara, Kanagawa, Япония, 2591193
- Novartis Investigative Site
-
Yokohama, Kanagawa, Япония, 2210855
- Novartis Investigative Site
-
-
Miyagi
-
Sendai, Miyagi, Япония, 9808574
- Novartis Investigative Site
-
-
Nagasaki
-
Nagasaki, Nagasaki, Япония, 8528501
- Novartis Investigative Site
-
-
Osaka
-
Sakai, Osaka, Япония, 5900197
- Novartis Investigative Site
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Япония, 1138603
- Novartis Investigative Site
-
tabashi City, Tokyo, Япония, 1738606
- Novartis Investigative Site
-
-
Yamaguchi
-
Shimonoseki, Yamaguchi, Япония, 7500061
- Novartis Investigative Site
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Patients diagnosed with MDS according to the WHO classification revised 4th edition by investigator assessment with one of the following prognostic risk categories, based on the International
Prognostic Scoring System (IPSS-R):
-
very low (0-1.5)
-
low (2-3)
-
intermediate risks (3.5-4.5) All following criteria for prognostic variables per IPSS-R should be met.
-
Bone marrow blast < 5% (per both investigator's assessment and central review)
-
Cytogenetic very good, good or intermediate risk corresponding to IPSS-R
- Platelet transfusion dependence
- Refractory, intolerant to, or ineligible for MDS treatments
- Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0 or 1
Exclusion Criteria:
- Patients with a history of prior administration of eltrombopag, romiplostim, or other TPO-RA
- Therapy-related MDS per WHO classification revised 4th edition
- MDS/myeloproliferative neoplasms including chronic myelomonocytic leukaemia per the WHO classification revised 4th edition
- MDS with excess blasts (EB) per WHO classification revised 4th edition
- Known history of IPSS-R high or very high risk MDS
- Currently receiving treatments for MDS (e.g., HMA, cyclosporine A (CsA) or lenalidomide). Supportive treatment with erythropoiesis-stimulating agents (ESAs) or erythroid mutation agent in anemic patients or granulocyte-colony stimulating factor (G-CSF) in patients with severe neutropenia and recurrent infections is allowed if at stable dosage for 3 months prior to screening and continued at the same dosing/schedule until the optimal dose of eltrombopag has been established.
- Patients scheduled for hematopoietic stem cell transplantation
- Bone marrow fibrosis that leads to an inability to aspirate adequate bone marrow sample
- Known thrombophilic risk factors (except in cases where potential benefits of participating in the study outweighed potential risks of thromboembolic events (TEE), as determined by the investigator)
Other protocol-defined inclusion/exclusion criteria may apply.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: Eltrombopag Arm
Participants randomized to a 1: 1 ratio will take eltrombopag. |
Eltrombopag comes in 12.5 mg & 25 mg tablets and is taken orally once per day (QD)
Другие имена:
|
|
Плацебо Компаратор: Placebo Arm
Participants randomized to a 1: 1 ratio will take Placebo. |
Placebo comes in 12.5 mg & 25 mg tablets and is taken orally once per day (QD) |
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percentage of participants who achieve platelet transfusion independence at Week 24
Временное ограничение: Week 24
|
Platelet transfusion independence is defined as the absence of platelet transfusion for at least 8 weeks. Platelet count should be higher than the baseline count. |
Week 24
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Time to platelet transfusion independence
Временное ограничение: Year 1, Year 2
|
This is defined as time from the date of randomization to the first day of a platelet transfusion-free period lasting at least 8 weeks. |
Year 1, Year 2
|
|
Duration of platelet transfusion independence
Временное ограничение: Year 1, Year 2
|
This is defined for participants who have achieved platelet transfusion independence only and will be calculated from the first date of platelet transfusion-free resulting in achievement of transfusion independence to the date before becoming platelet transfusion dependent. |
Year 1, Year 2
|
|
Percentage of participants with platelet transfusion independence
Временное ограничение: Year 1, Year 2
|
Platelet transfusion independence is defined as the absence of platelet transfusion for at least 8 weeks. Platelet count should be higher than the baseline count. |
Year 1, Year 2
|
|
Percentage of participants with platelet transfusion frequency reduction at Week 24
Временное ограничение: Week 24
|
This is defined as a reduction by at least 50 percent during the 4 prior weeks as compared to the 4 weeks prior to randomization. |
Week 24
|
|
Percentage of participants with platelet response (Hematologic improvement (HI) - platelet))
Временное ограничение: Week 24, Year 1, Year 2
|
Platelet response is defined as HI-platelet per International Working Group criteria. |
Week 24, Year 1, Year 2
|
|
Time to platelet response
Временное ограничение: Week 24, Year 1, Year 2
|
This is defined as time from the date of randomization to the first date of achieving the platelet response criteria per modified IWG criteria. |
Week 24, Year 1, Year 2
|
|
Duration of platelet response
Временное ограничение: Week 24, Year 1, Year 2
|
This is defined for participants who have achieved platelet response and will be calculated from the first date of achieving the platelet response criteria to the date before loss of platelet response per modified IWG criteria. |
Week 24, Year 1, Year 2
|
|
Percentage of hematologic improvement-erythroid and -neutrophil
Временное ограничение: Week 24, Year 1, Year 2
|
per modified IWG criteria at 24 weeks, Year 1 and 2 |
Week 24, Year 1, Year 2
|
|
Percentage of participants with disease progression excluding relapse after HI
Временное ограничение: Week 24, Year 1, Year 2
|
This is with regards to blast counts for both investigator assessment and central review per modified IWG criteria. |
Week 24, Year 1, Year 2
|
|
Percentage of participants with relapse after HI and transfusion independence
Временное ограничение: Week 24, Year 1, Year 2
|
The percentage of participants with relapse after HI and transfusion independence at Week 24, Year 1 and 2. |
Week 24, Year 1, Year 2
|
|
Percentage of participants with progression to Acute myeloid leukemia (AML)
Временное ограничение: Week 24, Year 1, Year 2
|
This is defined as ≥ 20% blasts at Week 24, Year 1 and 2 for both investigator assessment and central review per WHO classification revised 4th edition. |
Week 24, Year 1, Year 2
|
|
Leukemia free survival (LFS)
Временное ограничение: Week 24, Year 1, Year 2
|
This is defined as time from the date of randomization to progression to AML per WHO classification revised 4th edition of ≥ 20 percent blasts or death due to any cause for both investigator assessment and central review. |
Week 24, Year 1, Year 2
|
|
Clinically significant bleeding events
Временное ограничение: Week 24, Year 1, Year 2
|
This is defined as ≥ grade 2 events as per WHO bleeding scale. |
Week 24, Year 1, Year 2
|
|
Overall survival (OS)
Временное ограничение: Week 24, Year 1, Year 2
|
OS is defined as time from randomization to death due to any cause. |
Week 24, Year 1, Year 2
|
|
Quality of Life measured using QLQ-C30
Временное ограничение: Baseline, every 4 weeks until week 52, every 8 weeks after week 52 up to end of treatment or end of post-treatment follow-up, approximately 3.5 years.
|
The changes from baseline to each visit where measured using QLQ-C30. EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Subject's responses to 28 questions about their physical functioning, disease symptoms, global health status and utilities are scored on a 4-point scale (1=Not at all to 4=Very much), a low score indicates a high / healthy level of functioning. And the responses to 2 questions about health-related QoL are scored on a 7-point scale (1=Very poor to 7=Excellent), a high score indicates a high / healthy level of functioning. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. |
Baseline, every 4 weeks until week 52, every 8 weeks after week 52 up to end of treatment or end of post-treatment follow-up, approximately 3.5 years.
|
|
Pharmacokinetics (PK): Cmax
Временное ограничение: Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.
|
Full PK profile of eltrombopag over 24 hours at steady state at the initial dose, and at 125 mg and 150 mg when applicable, in subset of participants. |
Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.
|
|
PK: Tmax
Временное ограничение: Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.
|
Full PK profile of eltrombopag over 24 hours at steady state at the initial dose, and at 125 mg and 150 mg when applicable, in subset of participants. |
Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.
|
|
PK: AUC
Временное ограничение: Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.
|
Full PK profile of eltrombopag over 24 hours at steady state at the initial dose, and at 125 mg and 150 mg when applicable, in subset of participants. |
Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.
|
|
Trough concentrations of eltrombopag at steady state
Временное ограничение: Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.
|
at each dose level in all the participants |
Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.
|
Соавторы и исследователи
Спонсор
Спонсор
Следователи
Следователи
- Директор по исследованиям: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Начало исследования
Первичное завершение (Действительный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- CETB115L11201
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .